Chronic Back Pain denials in California external review
In the California DMHC record, independent physician reviewers decided 40 published external-review cases involving chronic back painand overturned the plan’s denial in 30%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for chronic back pain
| Category | Decisions | Overturned |
|---|---|---|
| Acupuncture | 4 | 0% |
| Oxycontin | 3 | 33.3% |
| Oxycodone-acetaminophen | 3 | 33.3% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 34 | 26.5% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 6 | 50% |
What the reviewers wrote
Where the denial was overturned
Standard Review Fulfills requirements of (1374.33) (h)(1)(A, B, C, D, G, H, I, K)Age: 44Gender: MNature of Statutory Criteria/Case Summary: The patient has requested reimbursement for all or any of the adult substance use disorder inpatient detoxification services provided at The Betty Ford Center. Per American Society of Addiction Medicine (ASAM) criteria, this patient met Level 3.5 criteria for inpatient detoxification services. ASAM criteria focuses on six dimensions to determine the appropriate level of care, which includes: (1) intoxication and withdrawal potential; (2) biomedical conditions; (3) emotional, behavioral and cognitive conditions; (4) readiness to change; (5) relapse, continued use, or continued problem potential; and (6) recovery environment. For dimension 1, the patient was placed on a suboxone taper and lorazepam taper for opioid withdrawal.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Oxycontin. On determining when to initiate or continue opioids for chronic pain, researchers report, “For patients already receiving opioid therapy, clinicians should carefully weigh benefits and risks and exercise care when changing opioid dosage. If benefits outweigh risks of continued opioid therapy, clinicians should work closely with patients to optimize nonopioid therapies while continuing opioid therapy. If benefits do not outweigh risks of continued opioid therapy, clinicians should optimize other therapies and work closely with patients to gradually taper to lower dosages or, if warranted based on the individual circumstances of the patient, appropriately taper and discontinue opioids.
Where the denial was upheld
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for an increase of Oxycontin from 15 milligrams (mg), two pills per day, to three pills per day for 30 days.The Centers for Disease Control and Prevention (CDC) guidelines for opioid therapy prescribing state that, “For patients already receiving opioid therapy, clinicians should carefully weigh benefits and risks and exercise care when changing opioid dosage. If benefits outweigh risks of continued opioid therapy, clinicians should work closely with patients to optimize nonopioid therapies while continuing opioid therapy”.
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Methadone 5mg - 112 tablets every 28 days. The Centers for Disease Control and Prevention (CDC) guidelines for opioid therapy prescribing state that, “For patients already receiving opioid therapy, clinicians should carefully weigh benefits and risks and exercise care when changing opioid dosage. If benefits outweigh risks of continued opioid therapy, clinicians should work closely with patients to optimize nonopioid therapies while continuing opioid therapy”. Further, the CDC advised that clinicians should optimize other therapies and work closely with patients to gradually taper to lower dosages or, if warranted based on the individual circumstances of the patient, appropriately taper and discontinue opioids so long as the benefits do not outweigh the risks of continued opioid therapy.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving chronic back pain, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY